Zevra Therapeutics (ZVRA) Competitors $7.32 +0.06 (+0.83%) Closing price 04:00 PM EasternExtended Trading$7.35 +0.03 (+0.42%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. ADPT, RXRX, ARQT, TVTX, DYN, BEAM, SRPT, IMCR, MESO, and APGEShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Arcutis Biotherapeutics (ARQT), Travere Therapeutics (TVTX), Dyne Therapeutics (DYN), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Immunocore (IMCR), Mesoblast (MESO), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Adaptive Biotechnologies Recursion Pharmaceuticals Arcutis Biotherapeutics Travere Therapeutics Dyne Therapeutics Beam Therapeutics Sarepta Therapeutics Immunocore Mesoblast Apogee Therapeutics Adaptive Biotechnologies (NASDAQ:ADPT) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment. Is ADPT or ZVRA more profitable? Zevra Therapeutics has a net margin of 4.33% compared to Adaptive Biotechnologies' net margin of -59.07%. Adaptive Biotechnologies' return on equity of -60.93% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% Zevra Therapeutics 4.33%-112.40%-37.67% Which has more risk and volatility, ADPT or ZVRA? Adaptive Biotechnologies has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Which has preferable earnings & valuation, ADPT or ZVRA? Zevra Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M10.90-$159.49M-$0.82-15.62Zevra Therapeutics$23.61M17.40-$105.51M-$0.21-34.86 Do analysts prefer ADPT or ZVRA? Adaptive Biotechnologies currently has a consensus target price of $12.38, indicating a potential downside of 3.40%. Zevra Therapeutics has a consensus target price of $23.71, indicating a potential upside of 223.97%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Does the media prefer ADPT or ZVRA? In the previous week, Zevra Therapeutics had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 9 mentions for Zevra Therapeutics and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.15 beat Zevra Therapeutics' score of 1.09 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ADPT or ZVRA? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 6.4% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAdaptive Biotechnologies and Zevra Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$410.87M$2.53B$5.73B$10.28BDividend YieldN/A56.56%5.88%4.63%P/E Ratio-34.8623.2976.6726.53Price / Sales17.40667.66525.87121.13Price / CashN/A169.4937.2060.52Price / Book9.895.2913.946.31Net Income-$105.51M$32.95M$3.29B$271.37M7 Day Performance-8.27%0.85%0.64%2.11%1 Month Performance-22.38%3.80%4.32%6.67%1 Year Performance-2.79%-3.96%84.14%27.85% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.9872 of 5 stars$7.32+0.8%$23.71+224.0%-6.7%$410.87M$23.61M-34.8620News CoveragePositive NewsHigh Trading VolumeADPTAdaptive Biotechnologies3.5348 of 5 stars$12.85-1.3%$12.38-3.7%+181.3%$1.98B$178.96M-15.67790Positive NewsRXRXRecursion Pharmaceuticals2.3145 of 5 stars$4.61+2.0%$7.25+57.3%-27.2%$1.96B$58.84M-2.59400ARQTArcutis Biotherapeutics2.2028 of 5 stars$17.15+5.8%$19.80+15.5%+67.0%$1.94B$196.54M-22.87150TVTXTravere Therapeutics2.9747 of 5 stars$21.64+2.3%$33.43+54.5%+59.6%$1.89B$233.18M-10.61460High Trading VolumeDYNDyne Therapeutics3.8719 of 5 stars$14.22+7.4%$34.07+139.6%-62.2%$1.88BN/A-3.68100Positive NewsBEAMBeam Therapeutics3.1911 of 5 stars$20.88+12.6%$48.45+132.1%-10.6%$1.88B$63.52M-4.64510Analyst DowngradeSRPTSarepta Therapeutics4.3549 of 5 stars$18.71+1.4%$43.50+132.5%-85.4%$1.80B$2.48B-21.511,372Analyst ForecastIMCRImmunocore2.0046 of 5 stars$37.20+5.5%$56.89+52.9%+2.5%$1.78B$310.20M-93.00320Insider TradeHigh Trading VolumeMESOMesoblast1.9723 of 5 stars$14.39+6.4%$18.00+25.1%+153.7%$1.73B$17.20M0.0080Positive NewsHigh Trading VolumeAPGEApogee Therapeutics2.7238 of 5 stars$37.87+2.0%$97.29+156.9%-28.5%$1.71BN/A-9.1791Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Recursion Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Travere Therapeutics Alternatives Dyne Therapeutics Alternatives Beam Therapeutics Alternatives Sarepta Therapeutics Alternatives Immunocore Alternatives Mesoblast Alternatives Apogee Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts